newsfilter
← Latest News
GlobeNewswire·

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

IMTX
  • One-time infusion of IMA203CD8 in platinum-resistant ovarian & uterine cancer showed a 63% objective response rate (ORR) & 50% confirmed ORR with four complete responses & longest ongoing response at 12 months.
  • Phase 1 data for synovial sarcoma patients demonstrated a 67% ORR & 64% confirmed ORR including one complete response with ongoing responses up to approximately 3 years.
  • IMA203CD8 demonstrated manageable & consistent tolerability across all patient populations with no related Grade 5 adverse events.
  • Clinical anti-tumor activity was observed across tumor types with distinct biology & varying PRAME expression levels including lower levels in ovarian carcinoma.
  • The clinical profile supports continued development in gynecologic cancers & expansion into other PRAME-positive solid tumors.
  • The recommended Phase 2 dose (RP2D) determination is expected in 2026.
  • Updated Phase 1 results for gynecologic cancers were presented on May 30, 2026, by Antonia Busse, M.D. at ASCO.
  • Synovial sarcoma Phase 1 data was presented on May 31, 2026, by Dejka M. Araujo, M.D. at ASCO.
  • In the gynecologic cancer cohort, 27 heavily pretreated patients received the infusion with median doses of 3.3x10^9 TCR T cells for ovarian carcinoma & 3.2x10^9 for uterine cancer.
  • Most frequent adverse events in gynecologic cancers were cytopenias associated with lymphodepletion & low-to-moderate grade cytokine release syndrome (CRS).
  • Synovial sarcoma patients had a 100% disease control rate at week 6 with a median duration of response of 14.8 months.
  • IMA203CD8 is a PRAME-directed TCR T-cell therapy engineered to recognize PRAME peptides presented by HLA-A*02:01.
  • PRAME is expressed in more than 50 cancers forming the basis of Immatics' broad therapeutic franchise.